Across TCGA pan-cancer cohorts, FAM230B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM230B data layer compared with 12 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM230B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM230B expression acts as an unfavorable survival marker.

UCEC, CHOL, and OV are the cancer types where FAM230B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.225	0.772	<.001	22	view →
CHOL	OS	Median	All	0.089	0.673	.018	9	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FAM230B tumor-vs-normal RNA expression · all FAM230B data types